Lung CancerNCT07073898
UG3 Pilot Clinical Trial
A study testing Repeated Text Messages (TM+), Conversational Agent (CA) and Educational Video in people with Lung Cancer, run by University of Utah at 1 site in United States.
Trial summary
LungSMART Utah utilizes a Population Health Management (PHM) approach that addresses key barriers to Lung Cancer Screening (LCS) implementation by deploying a centralized Hub infrastructure for eligibility assessment, individualized risk assessment and Shared Decision Making (SDM), LCS referral, and screening… Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Repeated Text Messages (TM+), Conversational Agent (CA) and Educational Video
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 65 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Sep 2025to 27 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Is currently a patient at Mountainlands CHCs
- Speak English or Spanish
- Current or former male or female smokers
- Age 50-80
- Have a phone that can receive text messages
- Electronic health records indicate they have not opted out of receiving text contact from the clinic
Who cannot join
- Persons with lung cancer or previous SDM
Trial locations and contacts
1 site in 1 country.
United States1 site
Huntsman Cancer Institute/ University of Utah
Salt Lake City, Utah, 84112
About this study
Official title: Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - UG3 Pilot Clinical Trial
LungSMART Utah utilizes a Population Health Management (PHM) approach that addresses key barriers to Lung Cancer Screening (LCS) implementation by deploying a centralized Hub infrastructure for eligibility assessment, individualized risk assessment and Shared Decision Making (SDM), LCS referral, and screening completion assistance, thereby increasing LCS reach at scale among Community Health Centers (CHCs) patients across the state of Utah.
Read the detailed description
LungSMART Utah is a Sequential Multiple Assignment Randomized Trial (SMART) that promotes the reach of lung cancer screening (LCS) among patients who receive medical services at Utah Community Health Centers (CHCs). The study design consists of two sequential stages: an Eligibility Assessment phase to identify and engage individuals at risk to participate in a shared decision-making (SDM) session to assess LCS eligibility, recommendation, and preference, followed by an LCS Completion phase to promote follow-through with recommended screening.
In this pilot trial, 50 current or former tobacco users aged 50-80 who receive medical services at the Mountainlands CHC and have no recorded history of lung cancer and have not participated in a SDM about LCS will be identified for the study. In the Eligibility Assessment Phase, patients will be assessed for LCS eligibility through digital health interventions and, if eligible, will engage with a qualified registered nurse (RN) at a centralized "Hub" for a SDM session, with and be offered a referral for LCS if screening is recommended and preferred. Phase 1 interventions include repeated text messaging (TM+), conversational agent (CA), and educational video (VID) to engage patients in a SDM session. The LCS Completion phase evaluates telehealth interventions designed to address logistical barriers and hesitancy among referred patients in completing LCS. Interventions include CA and either proactive- or reactive-patient navigation (PN) to increase LCS completion among CHC patients. Clinic staff will also be queried to examine if further refinement of research workflow and procedures is needed. Mountainlands CHC has agreed to partner with us to recruit patient participants for this pilot study.
- Conditions
- Lung Cancer
- Being tested
- Repeated Text Messages (TM+), Conversational Agent (CA), Educational Video, Proactive Patient Navigation (PPN), Reactive Patient Navigation (RPN)
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Repeated Text Messages (TM+)Other
The text message notifies patients that they may be eligible for LCS and provides the patient with a connection to an registered nurse (RN) for LCS eligibility assessment and Shared Decision-Making (SDM) discussion. Response options include YES (to request that the HUB RN call the patient) or STOP (to opt out of any further messages).
Conversational Agent (CA)Other
The CA is designed to address specific hesitancy factors and barriers to Lung Cancer Screening (LCS). The CA uses a rule-based approach. CAs use a predefined conversation script with a fixed set of possible questions and responses to educate patients regarding the importance of LCS and engage them to be connected with RN for eligibility assessment and SDM.
Educational VideoOther
The educational video provides patients with information and answers commonly asked questions about LCS.
Proactive Patient Navigation (PPN)Other
Proactive patient navigation enables trained navigators to actively identify and reach out to patients who may need assistance completing LCS, rather than waiting for patients to seek help on their own.
Reactive Patient Navigation (RPN)Other
Reactive patient navigation makes trained navigators available to those who seek assistance in completing LCS.
| Study group | Role | What they receive |
|---|---|---|
| Repeated Text Messages (TM+) | Other | Repeated text messages notifying patients that they may be eligible for Lung Cancer Screening (LCS). Receives: Other: Repeated Text Messages (TM+) |
| Repeated Text Messages plus a Conversational Agent (TM+, CA) | Other | Repeated text messages notifying patients that they may be eligible for LCS. In addition to text messages, patients will receive an automated, scripted, and interactive CA. Receives: Other: Repeated Text Messages (TM+); Other: Conversational Agent (CA) |
| Repeated Text Messages plus a Video (TM+, Video) | Other | Repeated text messages notifying patients that they may be eligible for LCS. In addition to text messages, patients will receive an educational video sent directly to their cell phone. Receives: Other: Repeated Text Messages (TM+); Other: Educational Video |
| Repeated Text Messages plus a Conversational Agent and Video (TM+, CA, Video) | Other | Repeated text messages notifying patients that they may be eligible for LCS. In addition to text messages, patients will receive an educational video sent directly to the patient's cell phone, along with a conversational agent to answer frequently asked LCS questions.
Additionally, patients will receive an educational video sent directly to the patient's cell phone and a chatbot to answer frequently asked LCS questions. Receives: Other: Repeated Text Messages (TM+); Other: Conversational Agent (CA); Other: Educational Video |
| CA/PPN | Other | A conversational agent to answer frequently asked LCS questions. In addition to proactive patient navigation. Receives: Other: Conversational Agent (CA); Other: Proactive Patient Navigation (PPN) |
| CA/RPN | Other | A conversational agent to answer frequently asked LCS questions. In addition to reactive patient navigation. Receives: Other: Conversational Agent (CA); Other: Reactive Patient Navigation (RPN) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Engagement - Lung Cancer Screening (LCS)
This outcome measure will report the proportion of enrolled subjects who engaged with Lung Cancer Screening (LCS) text messages during the study period.
LCS Engagement will be defined as any documented interaction with the text messaging system, as recorded by the study platform.
Measured: up to 3 months from study enrollment
Engagement - Shared Decision Making (SDM)
This outcome measure will report the proportion of enrolled subjects who engaged with Shared Decision Making (SDM) conversations during the study period.
SDM Engagement will be defined as any documented interaction with SDM conversations, as recorded in study documentation.
Measured: up to 3 months from study enrollment
Secondary outcomes (3)
Trustworthiness
Survey questions will measure engagement, trustworthiness, acceptability, and usefulness related to all interventions and content.
Text message trustworthiness is measured by two items that directly ask what made participants trust or not trust the initial text message. This outcome measure will report the proportion of subjects who reported text message trustworthiness.
Measured: up to 3 months from study enrollment
Acceptability
Survey questions will measure engagement, trustworthiness, acceptability, and usefulness related to all interventions and content.
Acceptability is measured as a composite of 4 dimensions:
- Frequency: 3 items about text message frequency and call attempt frequency
- Pace: 2 items about information delivery pace
- Process: 1 item about technical issues, 2 items regarding improvement suggestions, and 3 open-ended questions about the overall experience
- Content: 4 Yes/No items about the educational video in the branching logic section.
This outcome measure will report the proportion of subjects who reported text message acceptability.
Measured: up to 3 months from study enrollment
Usefulness
Survey questions will measure engagement, trustworthiness, acceptability, and usefulness related to all interventions and content.
Usefulness is measured as a composite of 4 dimensions:
- Perceived helpfulness: 1 question about the helpfulness of reminder texts, and 1 branching logic question about the helpfulness of additional information provided by the educational video that arrives via text.
- Confidence outcomes: 1 question measuring confidence in the next steps after shared decision-making
- Functional utility: 2 questions about opportunities to ask questions/express concerns and suggestions for additional valuable resources
- Overall utility: 2 closing questions about what worked well and the experience with the program.
This outcome measure will report the proportion of subjects who reported text message usefulness.
Measured: up to 3 months from study enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2025
- Study start26 Sep 2025
- Primary completion27 Jan 2026
- Study completion27 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (202)Papers the sponsor has linked to this study.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 65 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- David Wetter, Ph.D., Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07073898
- Sponsor's protocol ID
- HCI177308
- Other IDs
- UG3CA287109-02
- Status last verified
- Apr 2026
- First submitted
- 9 Jul 2025
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Fernandez ME, Schlechter CR, Del Fiol G, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Greene T, Nahum-Shani I, Schulthies S, Nelson M, Bohner C, Kramer H, Borbolla D, Austin S, Weir C, Walker TW, Lam CY, Wetter DW. QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers. Implement Sci. 2020 Jan 30;15(1):9. doi: 10.1186/s13012-020-0967-2.
PubMed 32000812Gibson B, Kramer H, Weir C, Fiol G, Borbolla D, Schlechter CR, Lam C, Nelson M, Bohner C, Schulthies S, Sieperas T, Pruhs A, Nahum-Shani I, Fernandez ME, Wetter DW. Workflow analysis for design of an electronic health record-based tobacco cessation intervention in community health centers. JAMIA Open. 2021 Feb 11;4(3):ooaa070. doi: 10.1093/jamiaopen/ooaa070. eCollection 2021 Jul.
PubMed 34514352Schlechter CR, Del Fiol G, Lam CY, Fernandez ME, Greene T, Yack M, Schulthies S, Nelson M, Bohner C, Pruhs A, Siaperas T, Kawamoto K, Gibson B, Nahum-Shani I, Walker TJ, Wetter DW. Application of community - engaged dissemination and implementation science to improve health equity. Prev Med Rep. 2021 Oct 26;24:101620. doi: 10.1016/j.pmedr.2021.101620. eCollection 2021 Dec.
PubMed 34976676Schlechter CR, Del Fiol G, Wetter DW, editors. Rapid and responsive interventions to address covid-19 and promote health equity. Proceedings of the 15th Annual Conference on the Science of Dissemination and Implementation in Health; 2022; Washington, DC, USA.
Fritz JM, Del Fiol G, Gibson B, Wetter DW, Solis V, Bennett E, Thackeray A, Goode A, Lundberg K, Romero A, Ford I, Stevens L, Siaperas T, Morales J, Yack M, Greene T. BeatPain Utah: study protocol for a pragmatic randomised trial examining telehealth strategies to provide non-pharmacologic pain care for persons with chronic low back pain receiving care in federally qualified health centers. BMJ Open. 2022 Nov 9;12(11):e067732. doi: 10.1136/bmjopen-2022-067732.
PubMed 36351735Viale PH. The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2020 Mar;11(2):135-136. doi: 10.6004/jadpro.2020.11.2.1. Epub 2020 Mar 1. No abstract available.
PubMed 33532112Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
PubMed 36633525American Cancer Society. Estimated number of deaths by state for 21 cancer sites, 2023. Atlanta, GA: American Cancer Society, 2023.
National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.
PubMed 21714641de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
PubMed 31995683Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Mar 4;160(5):330-8. doi: 10.7326/M13-2771.
PubMed 24378917US Preventive Services Task Force. Final recommendation statement: lung cancer screening (2013) 2013 [04/04/2021]. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screeningdecember-2013
Zhao H, Xu Y, Huo J, Burks AC, Ost DE, Shih YT. Updated Analysis of Complication Rates Associated With Invasive Diagnostic Procedures After Lung Cancer Screening. JAMA Netw Open. 2020 Dec 1;3(12):e2029874. doi: 10.1001/jamanetworkopen.2020.29874.
PubMed 33326023Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, Chaturvedi AK, Silvestri GA, Riley TL, Commins J, Berg CD. Selection criteria for lung-cancer screening. N Engl J Med. 2013 Feb 21;368(8):728-36. doi: 10.1056/NEJMoa1211776.
PubMed 23425165Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, Silvestri GA, Chaturvedi AK, Katki HA. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013 Jul 18;369(3):245-254. doi: 10.1056/NEJMoa1301851.
PubMed 23863051
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Population Health Management Approaches to Increase Lung Cancer Screening in Community Health Centers - UG3 Pilot Clinical Trial
- ClinicalTrials.gov ID
- NCT07073898
- Acronym / sponsor ID
- HCI177308
- Conditions
- Lung Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 65 participants (actual)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 26 Sep 2025 (actual)
- Primary completion
- 27 Jan 2026 (actual)
- Study completion
- 27 Jan 2026 (actual)
- First posted
- 18 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
LungSMART Utah utilizes a Population Health Management (PHM) approach that addresses key barriers to Lung Cancer Screening (LCS) implementation by deploying a centralized Hub infrastructure for eligibility assessment, individualized risk assessment and Shared Decision Making (SDM), LCS referral, and screening completion assistance, thereby increasing LCS reach at scale among Community Health Centers (CHCs) patients across the state of Utah.
Detailed description
LungSMART Utah is a Sequential Multiple Assignment Randomized Trial (SMART) that promotes the reach of lung cancer screening (LCS) among patients who receive medical services at Utah Community Health Centers (CHCs). The study design consists of two sequential stages: an Eligibility Assessment phase to identify and engage individuals at risk to participate in a shared decision-making (SDM) session to assess LCS eligibility, recommendation, and preference, followed by an LCS Completion phase to promote follow-through with recommended screening.
In this pilot trial, 50 current or former tobacco users aged 50-80 who receive medical services at the Mountainlands CHC and have no recorded history of lung cancer and have not participated in a SDM about LCS will be identified for the study. In the Eligibility Assessment Phase, patients will be assessed for LCS eligibility through digital health interventions and, if eligible, will engage with a qualified registered nurse (RN) at a centralized "Hub" for a SDM session, with and be offered a referral for LCS if screening is recommended and preferred. Phase 1 interventions include repeated text messaging (TM+), conversational agent (CA), and educational video (VID) to engage patients in a SDM session. The LCS Completion phase evaluates telehealth interventions designed to address logistical barriers and hesitancy among referred patients in completing LCS. Interventions include CA and either proactive- or reactive-patient navigation (PN) to increase LCS completion among CHC patients. Clinic staff will also be queried to examine if further refinement of research workflow and procedures is needed. Mountainlands CHC has agreed to partner with us to recruit patient participants for this pilot study.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Repeated Text Messages (TM+) | Other | Other: Repeated Text Messages (TM+)Repeated text messages notifying patients that they may be eligible for Lung Cancer Screening (LCS). |
| Repeated Text Messages plus a Conversational Agent (TM+, CA) | Other | Other: Repeated Text Messages (TM+), Other: Conversational Agent (CA)Repeated text messages notifying patients that they may be eligible for LCS. In addition to text messages, patients will receive an automated, scripted, and interactive CA. |
| Repeated Text Messages plus a Video (TM+, Video) | Other | Other: Repeated Text Messages (TM+), Other: Educational VideoRepeated text messages notifying patients that they may be eligible for LCS. In addition to text messages, patients will receive an educational video sent directly to their cell phone. |
| Repeated Text Messages plus a Conversational Agent and Video (TM+, CA, Video) | Other | Other: Repeated Text Messages (TM+), Other: Conversational Agent (CA), Other: Educational VideoRepeated text messages notifying patients that they may be eligible for LCS. In addition to text messages, patients will receive an educational video sent directly to the patient's cell phone, along with a conversational agent to answer frequently asked LCS questions. Additionally, patients will receive an educational video sent directly to the patient's cell phone and a chatbot to answer frequently asked LCS questions. |
| CA/PPN | Other | Other: Conversational Agent (CA), Other: Proactive Patient Navigation (PPN)A conversational agent to answer frequently asked LCS questions. In addition to proactive patient navigation. |
| CA/RPN | Other | Other: Conversational Agent (CA), Other: Reactive Patient Navigation (RPN)A conversational agent to answer frequently asked LCS questions. In addition to reactive patient navigation. |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Is currently a patient at Mountainlands CHCs
- Speak English or Spanish
- Current or former male or female smokers
- Age 50-80
- Have a phone that can receive text messages
Key exclusion criteria (1 listed)
- Persons with lung cancer or previous SDM
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Repeated Text Messages (TM+)The text message notifies patients that they may be eligible for LCS and provides the patient with a connection to an registered nurse (RN) for LCS eligibility assessment and Shared Decision-Making (SDM) discussion. Response options include YES (to request that the HUB RN call the patient) or STOP (to opt out of any further messages). | Other | Repeated Text Messages (TM+), Repeated Text Messages plus a Conversational Agent (TM+, CA), Repeated Text Messages plus a Conversational Agent and Video (TM+, CA, Video), Repeated Text Messages plus a Video (TM+, Video) |
| Conversational Agent (CA)The CA is designed to address specific hesitancy factors and barriers to Lung Cancer Screening (LCS). The CA uses a rule-based approach. CAs use a predefined conversation script with a fixed set of possible questions and responses to educate patients regarding the importance of LCS and engage them to be connected with RN for eligibility assessment and SDM. | Other | CA/PPN, CA/RPN, Repeated Text Messages plus a Conversational Agent (TM+, CA), Repeated Text Messages plus a Conversational Agent and Video (TM+, CA, Video) |
| Educational VideoThe educational video provides patients with information and answers commonly asked questions about LCS. | Other | Repeated Text Messages plus a Conversational Agent and Video (TM+, CA, Video), Repeated Text Messages plus a Video (TM+, Video) |
| Proactive Patient Navigation (PPN)Proactive patient navigation enables trained navigators to actively identify and reach out to patients who may need assistance completing LCS, rather than waiting for patients to seek help on their own. | Other | CA/PPN |
| Reactive Patient Navigation (RPN)Reactive patient navigation makes trained navigators available to those who seek assistance in completing LCS. | Other | CA/RPN |
Primary outcome
Engagement - Lung Cancer Screening (LCS)
Time frame: up to 3 months from study enrollment
This outcome measure will report the proportion of enrolled subjects who engaged with Lung Cancer Screening (LCS) text messages during the study period. LCS Engagement will be defined as any documented interaction with the text messaging system, as recorded by the study platform.
Engagement - Shared Decision Making (SDM)
Time frame: up to 3 months from study enrollment
This outcome measure will report the proportion of enrolled subjects who engaged with Shared Decision Making (SDM) conversations during the study period. SDM Engagement will be defined as any documented interaction with SDM conversations, as recorded in study documentation.
3 secondary outcomes
Trustworthiness
Time frame: up to 3 months from study enrollment
Acceptability
Time frame: up to 3 months from study enrollment
Usefulness
Time frame: up to 3 months from study enrollment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2026.
- Background: PubMed 32000812Fernandez ME, Schlechter CR, Del Fiol G, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Greene T, Nahum-Shani I, Schulthies S, Nelson M, Bohner C, Kramer H, Borbolla D, Austin S, Weir C, Walker TW, Lam CY, Wetter DW. QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers. Implement Sci. 2020 Jan 30;15(1):9. doi: 10.1186/s13012-020-0967-2.
- Background: PubMed 34514352Gibson B, Kramer H, Weir C, Fiol G, Borbolla D, Schlechter CR, Lam C, Nelson M, Bohner C, Schulthies S, Sieperas T, Pruhs A, Nahum-Shani I, Fernandez ME, Wetter DW. Workflow analysis for design of an electronic health record-based tobacco cessation intervention in community health centers. JAMIA Open. 2021 Feb 11;4(3):ooaa070. doi: 10.1093/jamiaopen/ooaa070. eCollection 2021 Jul.
- Background: PubMed 34976676Schlechter CR, Del Fiol G, Lam CY, Fernandez ME, Greene T, Yack M, Schulthies S, Nelson M, Bohner C, Pruhs A, Siaperas T, Kawamoto K, Gibson B, Nahum-Shani I, Walker TJ, Wetter DW. Application of community - engaged dissemination and implementation science to improve health equity. Prev Med Rep. 2021 Oct 26;24:101620. doi: 10.1016/j.pmedr.2021.101620. eCollection 2021 Dec.
- BackgroundSchlechter CR, Del Fiol G, Wetter DW, editors. Rapid and responsive interventions to address covid-19 and promote health equity. Proceedings of the 15th Annual Conference on the Science of Dissemination and Implementation in Health; 2022; Washington, DC, USA.
- Background: PubMed 36351735Fritz JM, Del Fiol G, Gibson B, Wetter DW, Solis V, Bennett E, Thackeray A, Goode A, Lundberg K, Romero A, Ford I, Stevens L, Siaperas T, Morales J, Yack M, Greene T. BeatPain Utah: study protocol for a pragmatic randomised trial examining telehealth strategies to provide non-pharmacologic pain care for persons with chronic low back pain receiving care in federally qualified health centers. BMJ Open. 2022 Nov 9;12(11):e067732. doi: 10.1136/bmjopen-2022-067732.
- Background: PubMed 33532112Viale PH. The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2020 Mar;11(2):135-136. doi: 10.6004/jadpro.2020.11.2.1. Epub 2020 Mar 1. No abstract available.
- Background: PubMed 36633525Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
- BackgroundAmerican Cancer Society. Estimated number of deaths by state for 21 cancer sites, 2023. Atlanta, GA: American Cancer Society, 2023.
- Background: PubMed 21714641National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.
- Background: PubMed 31995683de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
- Background: PubMed 24378917Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Mar 4;160(5):330-8. doi: 10.7326/M13-2771.
- BackgroundUS Preventive Services Task Force. Final recommendation statement: lung cancer screening (2013) 2013 [04/04/2021]. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screeningdecember-2013
Related trials for Lung Cancer
RecruitingPhase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-small-Cell Lung
RecruitingPhase 1/2
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ovarian Cancer, Non-small Cell Lung Cancer
Active, not recruiting
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Bone Metastases, HER2-positive Breast Cancer
Not yet recruitingObservational study
The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer
Rheumatoid Arthritis (RA), Lung Neoplasms
Active, not recruitingPhase 3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Advanced or Metastatic Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Wetter, Ph.D. principal investigator
Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Repeated Text Messages (TM+), Conversational Agent (CA) and Educational Video in people with Lung Cancer, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Engagement - Lung Cancer Screening (LCS) (time frame: up to 3 months from study enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07073898, which also lists 202 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.